Along the same lines, we also observed overexpression of baseline BMP2 in patients whose disease relapsed and overexpression of BMP5 in patients whose EDSS improved, indicating dysregulation of BMP signaling in MS patients. Here, BMP2 is linked to myeloid sarcoma.